Ask the experts: Future of the pharmaceutical industry

Future Medicinal Chemistry

Volumn 3, Issue 15, 2011, Pages 1863-1872

  Cottens, Sylvain ^a   Eaton, Mike ^b   Fuhr, Joseph ^c   Geary, Stewart ^b   Johnson, Douglas S ^d   Li, Ge ^e   Raveglia, Luca ^f   Robertson, Graeme M ^g   Westwell, Andrew ^h  

^a Institutes for Biomedical Research   (Switzerland)

^b ETP Nanomedicine ^*  (Japan)

^c WIDENER UNIVERSITY   (United States)

^d PFIZER INC   (United States)

^e WuXi AppTec Co   (United States)

^f NiKem Research   (Italy)

^g UNIVERSITY OF PERUGIA   (Italy)

^h CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; NANOMEDICINE; NOTE; PATENT; PRIORITY JOURNAL;

DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; INDIVIDUALIZED MEDICINE; PATENTS AS TOPIC; RESEARCH;

EID: 80054945024     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.145     Document Type: Note

References (2)

1. Eaton M. Nanotechnology, biology and innovation. Nanomedicine 7, 371-375 (2011).
2. Johnson DS, Stiff C, Lazerwith SE. Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor. ACS Med. Chem. 2(2), 91-96 (2011).